TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01228773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored web-based care program (Health Navigation®)
Description: When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored web-based care program (Health Navigation®)
Description: When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
Study: NCT03783156

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hot snare
Description: polypectomy with hot snare

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cold snare
Description: polypectomy with cold snare
Study: NCT04203173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FINANCE-DM
Description: The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session. Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
Study: NCT01319162

Intervention type: OTHER
Intervention: Weight reduction regimen
Description: The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (\<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.

Intervention type: OTHER
Intervention: Weight reduction regimen
Description: The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (\<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
Study: NCT04798144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distilled water irrigation kept at 2.5°C degree
Description: The use of cold distilled water for final irrigation of root canal system during root canal treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water irrigation kept at room temperature
Description: The use of distilled water kept at room temperature for final irrigation of root canal system during root canal treatment
Study: NCT02875769

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dental prophylaxis
Description: Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dental prophylaxis
Description: Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental prophylaxis
Description: Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental prophylaxis
Description: Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash CPC+Zn+F
Description: The volunteer rinsed with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base for one minute, 20 ml of solution and then expectorated all remaining liquid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash CHX
Description: The volunteer rinsed with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol for one minute, 20 ml of solution and then expectorated all remaining liquid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No rinsing
Description: The volunteer did not rinse with any pre-procedural mothwash.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: The volunteer rinsed with pre-procedural mouthwash containing water from a three-way syringe for one minute, 20 ml of water and then expectorated all remaining liquid.
Study: NCT00620074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance \<50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anidulafungin
Description: Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
Study: NCT04678141

Intervention type: OTHER
Group type: OTHER
Intervention: Dyract XP (Dentsply De Trey), Kerr Herculite Classic (Kerr Corporation),R&D Series NOVA(Kuraray Medical Inc) Clearfil TM SE Bond (Kuraray Medical),Hydrocal LC (Medicept Dental)
Description: compomer (Dyract XP,R\&D Series NOVA) , composite (Kerr Herculite Classic),Bonding (Clearfil TM SE Bond), Dycall (Hydrocal LC)
Study: NCT04875117

Intervention type: DEVICE
Intervention: Hearing aid
Description: One or two behind the ear hearing aids provided by the UK National Health Service.
Study: NCT01802320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02262611

Intervention type: DRUG
Intervention: MicardisPlus®

Intervention type: DRUG
Intervention: MicardisPlus®
Study: NCT04390256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clove water extract
Description: natural product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clove water extract
Description: natural product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clove water extract
Description: natural product

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clove water extract
Description: natural product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbopol
Description: Bioadhesive polymer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbopol
Description: Bioadhesive polymer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbopol
Description: Bioadhesive polymer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbopol
Description: Bioadhesive polymer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboxymethyle cellulose
Description: Bioadhesive polymer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboxymethyle cellulose
Description: Bioadhesive polymer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboxymethyle cellulose
Description: Bioadhesive polymer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethyle cellulose
Description: Bioadhesive polymer
Study: NCT01350908

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: 30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
Study: NCT01631331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mohs surgery
Description: Undergo Mohs surgery
Study: NCT00670761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MVA
Description: comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
Study: NCT03266393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: Once daily sustained-release tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: Once daily sustained-release tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Twice daily immediate-release tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Twice daily immediate-release tacrolimus
Study: NCT00164463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg po qd 5/7 days per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: isoniazid 300 mg po qd 5/7 days per week
Study: NCT03588923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH229
Description: tablet, oral, 400 mg once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: tablet, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH229
Description: tablet, oral, 600 mg once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: tablet, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH229
Description: tablet, oral, 800 mg once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: tablet, oral, once daily for 3 days
Study: NCT00908128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 500 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept®
Description: CellCept® Tablets, 500 mg
Study: NCT03077880

Intervention type: PROCEDURE
Intervention: intra-operatory measurement during implant placement
Description: mucoperiosteal flap, soft tissue thickness measurement, implant insertion

Intervention type: PROCEDURE
Intervention: intra-operatory measurement during implant placement
Description: mucoperiosteal flap, soft tissue thickness measurement, implant insertion
Study: NCT02517294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parker flex-tip nasotracheal tube
Description: specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard nasotracheal tube
Description: standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
Study: NCT03113708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Sodium
Description: Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Heparin Sodium
Description: Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
Study: NCT00649987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate Extended-Release Tablets 8 mg
Description: 8mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VoSpire® ER Tablets 8 mg
Description: 8mg, single dose fed
Study: NCT03967938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Capsule
Description: Olaparib tablets 300mg twice daily
Study: NCT03948100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Undergo dyadic education program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Undergo dyadic yoga
Study: NCT00268879

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Renzapride
Description: Placebo Renzapride 4 mg QD Renzapride 2 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renzapride
Description: Placebo Renzapride 4 mg QD Renzapride 2 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renzapride
Description: Placebo Renzapride 4 mg QD Renzapride 2 mg BID
Study: NCT04677075

Intervention type: PROCEDURE
Intervention: mastectomy
Description: mastectomy either simple or modified radical
Study: NCT02350231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The progesterone vaginal pessary
Description: Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tonics group
Description: Those patients will receive only tonics
Study: NCT01058668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
Study: NCT01601158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood administration
Description: The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
Study: NCT04443907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OTQ923
Description: Single intravenous infusion of OTQ923 cell suspension

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OTQ923
Description: Single intravenous infusion of OTQ923, based on review of data from Part A by Health agencies after a formal interim analysis
Study: NCT01463423

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 25 Gray in 1 fraction for small peripheral tumors
Description: Radiotherapy procedure for participants with small peripheral tumors ≤ 10 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 25 Gray in 1 fraction for small peripheral tumors
Description: Radiotherapy procedure for participants with small peripheral tumors ≤ 10 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 25 Gray in 1 fraction for small peripheral tumors
Description: Radiotherapy procedure for participants with small peripheral tumors ≤ 10 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 50 Gray in 4 fractions for medium peripheral tumors
Description: Radiotherapy procedure for participants with medium peripheral tumors \> 10 cc and ≤ 30 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 50 Gray in 4 fractions for medium peripheral tumors
Description: Radiotherapy procedure for participants with medium peripheral tumors \> 10 cc and ≤ 30 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 50 Gray in 4 fractions for medium peripheral tumors
Description: Radiotherapy procedure for participants with medium peripheral tumors \> 10 cc and ≤ 30 cc.
Study: NCT03304314

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: objective chromatic multifocal pupillometer
Description: objective chromatic multifocal pupillometer (OCMP) enables objective and accurate measurement of pupillary responses to chromatic light at different wavelengths and light intensities and at different visual field locations.
Study: NCT01463423

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 54 Gray in 3 fractions for large peripheral tumors
Description: Radiotherapy procedure for participants with large peripheral tumors \> 30 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 54 Gray in 3 fractions for large peripheral tumors
Description: Radiotherapy procedure for participants with large peripheral tumors \> 30 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 54 Gray in 3 fractions for large peripheral tumors
Description: Radiotherapy procedure for participants with large peripheral tumors \> 30 cc.
Study: NCT04308889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza contains ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources.
Study: NCT01463423

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 40 Gray in 4 fractions for small central tumors
Description: Radiotherapy procedure for participants with small central tumors ≤ 10 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 40 Gray in 4 fractions for small central tumors
Description: Radiotherapy procedure for participants with small central tumors ≤ 10 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 40 Gray in 4 fractions for small central tumors
Description: Radiotherapy procedure for participants with small central tumors ≤ 10 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 50 Gray in 4 fractions for medium central tumors
Description: Radiotherapy procedure for participants with medium central tumors \> 10 cc and ≤ 30 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 50 Gray in 4 fractions for medium central tumors
Description: Radiotherapy procedure for participants with medium central tumors \> 10 cc and ≤ 30 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 50 Gray in 4 fractions for medium central tumors
Description: Radiotherapy procedure for participants with medium central tumors \> 10 cc and ≤ 30 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 60 Gray in 8 fractions for large central tumors
Description: Radiotherapy procedure for participants with large central tumors \> 30 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 60 Gray in 8 fractions for large central tumors
Description: Radiotherapy procedure for participants with large central tumors \> 30 cc.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iSABR, 60 Gray in 8 fractions for large central tumors
Description: Radiotherapy procedure for participants with large central tumors \> 30 cc.
Study: NCT02141919

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation Therapy
Description: Stereotactic Ablative Body Radiation Therapy (SABR): 3 fractions of 12Gy, or 4 fractions of 10Gy or 5 fractions of 8 Gy
Study: NCT01030328

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 sugar pills by mouth once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TriLipix
Description: 135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day